Mydecine Innovations Group Provides Update on European Operations Company Appoints Former Novartis Norway CEO as President of European Operations, and Partners with Dr. David Erritzoe in the set up of a novel collaborative psychopharmacology/psychedelic research clinic between Imperial College London and a major mental health NHS Trust in London Mydecine Innovations Group Inc.
DENVER, March 16, 2021 (GLOBE NEWSWIRE)
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has appointed Michel Rudolphie, former CEO and President of Make-A-Wish International and former Novartis Norway CEO, as President of the Company’s European Operations. In addition to adding new leadership, the Company also announces that it has partner
IRW-News: Mydecine Innovations Group Inc : Mydecine Innovations Group gibt aktuelle Informationen zu den europäischen Geschäftsabläufen bekannt
boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.
Mydecine Innovations Group Provides Update on European Operations
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.